Acorda Therapeutics, Inc. ACOR, -0.82% a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological disorders, will visit the Nasdaq MarketSite in Times Square to mark the 20th …
Market Watch · 3/13/2015
Acorda Therapeutics ($ACOR) moved a step closer to collecting the payoff from ... the company announced at an international Parkinson's conference in San Diego, CA, pushing its stock up 3.5%. And the improvement was apparent 10 minutes after …
Fierce Drug Delivery · 6/23/2015
Phase II trials
Acorda Therapeutics (NASDAQ:ACOR) insider Andrew A. Hindman sold 4,779 shares of the stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $29.82, for a total value of $142,509.78. Following the transaction, the … · 5/16/2015
More from Bing News
Stifel commented on Acorda Therapeutics Inc (NASDAQ: ACOR) Wednesday after the stock fell from approximately ... “At about 2:00, the Coalition for Affordable drugs (CFAD) filed a petition (IPR2015-00720) for an Inter Partes Review (IPR is legalese ...
Benzinga · 2/12/2015
I took a small position in Acorda Therapeutics (NASDAQ:ACOR) last year after I heard of its plans to acquire Civitas. The stock rallied there after touching a high of $45.45 and more recently towards its price today below $30/share mark. The sell off this ...
Seeking Alpha · 5/1/2015
On Wednesday, small cap Acorda Therapeutics surged 28.18% to $37.62 (ACOR has a 52 week trading range of $27.51 to $39.94 a share) for a market cap of $1.23 billion plus the stock is up 30.2% since the start of the year, up 7.5% over the past year …
Smallcap Network · ByJohn Udovich · 9/26/2014
Acorda Therapeutics's stock is up 1.3% to $31.80 on heavy trading volume. Approximately 897,000 shares have changed hands today vs. average 30-day volume of 601,000 shares. Spikes in volume can validate a breakout or signify a potential turning point.
Financial News Network Online · ByAdrienne Chilton · 5/20/2015
Ardelyx, Inc. (ARDX)’s monthly performance stands at -18.900% and Ardelyx, Inc. (ARDX) is considered a stock to watch with an analyst rating of 1.30 Acorda Therapeutics, Inc. (ACOR) of the Healthcare sector (Biotechnology) has a change of 2.28% per … · 3/27/2015
Echo Therapeutics (Nasdaq: ECTE) 64% LOWER; announced that, as it believes that its current liquidity is insufficient to fund its needs beyond September 30, 2014, it has suspended its product development, research, manufacturing and clinical programs …
StreetInsider · 9/24/2014